Adalank (N-Acetyl Selank Amidate) record · updated 6h ago
Adalank (N-Acetyl Selank Amidate) is a modified analog of the Russian heptapeptide Selank, designed for enhanced metabolic stability and investigated for anxiolytic and nootropic effects.
How it works: Anxiolytic heptapeptide (Tuftsin analog)
Development stage
where Adalank (N-Acetyl Selank Amidate) sits between preclinical work and regulatory approval- 1CurrentPreclinicalAnimal / in-vitro work
- 2Not reachedPhase 1Safety in humans
- 3Not reachedPhase 2Efficacy signal
- 4Not reachedPhase 3Confirmatory trials
- 5Not reachedApprovedCleared by a regulator
Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.
No study in this library has tested Adalank. Adalank is a chemically modified form of Selank, and the papers below examined Selank — each row is labelled with the compound that study actually looked at.
Adalank is not Selank. Altering a molecule — adding a group to it, or keeping only part of the chain — can change what it binds to, how much of it reaches the target, how long it lasts and what it does at a given dose. None of that was measured below. Research on Selank is not evidence that Adalank does the same thing, or that it is as safe.
What people are saying
anecdotal · not evidenceUnverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Adalank (N-Acetyl Selank Amidate) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.